
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
4519 | Tokyo | JPY | Delayed | |
CHGCY | OTC Markets | USD | Delayed | |
4519 | Frankfurt | EUR | Delayed |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology; and research and license agreement with Gero PTE. LTD. to develop novel therapies for age-related diseases. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. Chugai Pharmaceutical Co., Ltd. was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
Name | Age | Since | Title |
---|---|---|---|
Shigehiro Yamada | 60 | 2019 | Full-Time Audit & Supervisory Board Member |
Iwaaki Taniguchi | 57 | 2022 | Executive VP, Head of Finance Supervisory Division, CFO & Director |
Kenichi Masuda | 62 | 2020 | Outside Independent Audit & Supervisory Board Member |
William A. M. Burns | 78 | - | Member of the International Advisory Council |
Fumio Tateishi | 76 | 2023 | Outside Independent Director |
Hideo Teramoto | 65 | 2023 | Outside Independent Director |
Andrew C. von Eschenbach | 83 | - | Member of the International Advisory Council |
Sonosuke Kadonaga | 73 | - | Member of the International Advisory Council |
Teresa A. Graham | 52 | 2023 | Non-Executive Director |
Yumiko Waseda | 65 | 2023 | Outside Independent Audit & Supervisory Board Member |
Mami Yunoki | 62 | 2024 | Outside Independent Audit & Supervisory Board Member |
Victor Halberstadt | - | - | Member of the International Advisory Council |
Franz Bernhard Humer | 79 | 2014 | Member of the International Advisory Council |
Arnold J. Levine | 85 | - | Member of the International Advisory Council |
Henry L. Nordhoff | 83 | - | Chairman of the International Advisory Council |
Virginia Hilda Brunette Maxwell Bottomley | 77 | - | Member of the International Advisory Council |
Mariko Y. Momoi | 77 | 2020 | Outside Independent Director |
Boris L. Zaitra | 53 | 2025 | Director |
Hitoshi Iikura | 55 | 2024 | Executive VP, Head of Translational Research Division & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review